VIPR2 Antibody - #DF5173

(1)   (5)  
Product: VIPR2 Antibody
Catalog: DF5173
Description: Rabbit polyclonal antibody to VIPR2
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 49 KD; 49kD(Calculated).
Uniprot: P41587
RRID: AB_2837522

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:1000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(80%), Sheep(100%), Rabbit(80%), Dog(80%)
Clonality:
Polyclonal
Specificity:
VIPR2 Antibody detects endogenous levels of total VIPR2.
RRID:
AB_2837522
Cite Format: Affinity Biosciences Cat# DF5173, RRID:AB_2837522.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Helodermin-preferring VIP receptor; PACAP type III receptor; PACAP-R-3; PACAP-R3; Pituitary adenylate cyclase-activating polypeptide type III receptor; Vasoactive intestinal polypeptide receptor 2; VIP Receptor 2; VIP-R-2; Vipr2; VIPR2_HUMAN; VPAC2 receptor;

Immunogens

Immunogen:
Uniprot:

P41587(VIPR2_HUMAN) >>Visit HPA database.

Gene(ID):
VIPR2(7434)
Expression:
P41587 VIPR2_HUMAN:

Expressed in CD4+ T-cells, but not in CD8+ T-cells. Expressed in the T-cell lines Jurkat, Peer, MOLT-4, HSB, YT and SUP-T1, but not in the T-cell lines HARRIS and HuT 78.

Sequence:
MRTLLPPALLTCWLLAPVNSIHPECRFHLEIQEEETKCAELLRSQTEKHKACSGVWDNITCWRPANVGETVTVPCPKVFSNFYSKAGNISKNCTSDGWSETFPDFVDACGYSDPEDESKITFYILVKAIYTLGYSVSLMSLATGSIILCLFRKLHCTRNYIHLNLFLSFILRAISVLVKDDVLYSSSGTLHCPDQPSSWVGCKLSLVFLQYCIMANFFWLLVEGLYLHTLLVAMLPPRRCFLAYLLIGWGLPTVCIGAWTAARLYLEDTGCWDTNDHSVPWWVIRIPILISIIVNFVLFISIIRILLQKLTSPDVGGNDQSQYKRLAKSTLLLIPLFGVHYMVFAVFPISISSKYQILFELCLGSFQGLVVAVLYCFLNSEVQCELKRKWRSRCPTPSASRDYRVCGSSFSRNGSEGALQFHRGSRAQSFLQTETSVI

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Sheep
100
Horse
80
Dog
80
Rabbit
80
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P41587 As Substrate

Site PTM Type Enzyme
S409 Phosphorylation
S415 Phosphorylation
S429 Phosphorylation

Research Backgrounds

Function:

This is a receptor for VIP as well as PACAP-38 and -27, the activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Can be coupled to phospholipase C.

Subcellular Location:

Cell membrane>Multi-pass membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in CD4+ T-cells, but not in CD8+ T-cells. Expressed in the T-cell lines Jurkat, Peer, MOLT-4, HSB, YT and SUP-T1, but not in the T-cell lines HARRIS and HuT 78.

Family&Domains:

Belongs to the G-protein coupled receptor 2 family.

Research Fields

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Neuroactive ligand-receptor interaction.

References

1). Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4+ type 9 helper T cells and the VIP–VPAC2 signalling pathway. PHARMACEUTICAL BIOLOGY, 2021 (PubMed: 34493162) [IF=3.8]

Application: IF/ICC    Species: Mice    Sample: lung tissues

Figure 9. Effects of M-BYF on VPAC2 expression and VPAC2+CD90+ cells in OVA-induced asthmatic mice. (A) Representative immunofluorescent staining images of VPAC2 and VPAC2+CD90+ cells. VPAC2 staining as shown in red. CD90 staining as shown in green. Scale bar: 50 µm and 20 µm. (B, C) The protein expression of VPAC2 in lungs was detected by western blot and densitometric analysis was performed. M-BYF reduced the expression of VPAC2 protein in lungs of asthmatic mice as compared with the Model group (D) Quantification of VPAC2+CD90+ cells showed that M-BYF reduced percentage of VPAC2+CD90+ cells in lungs of asthmatic mice as compared with the Model group. Four non-consecutive sections from each animal were averaged and compared among experimental groups; n = 3 in each group. Data are represented as mean ± S.E.M. (ΔΔΔp < 0.001, Δp < 0.05 compared with the Control group; ***p < 0.001, **p < 0.01 and *p < 0.05 compared with the Model group; #p < 0.05 compared with the dexamethasone treated group.)

Application: WB    Species: Mice    Sample: lung tissues

Figure 9. Effects of M-BYF on VPAC2 expression and VPAC2+CD90+ cells in OVA-induced asthmatic mice. (A) Representative immunofluorescent staining images of VPAC2 and VPAC2+CD90+ cells. VPAC2 staining as shown in red. CD90 staining as shown in green. Scale bar: 50 µm and 20 µm. (B, C) The protein expression of VPAC2 in lungs was detected by western blot and densitometric analysis was performed. M-BYF reduced the expression of VPAC2 protein in lungs of asthmatic mice as compared with the Model group (D) Quantification of VPAC2+CD90+ cells showed that M-BYF reduced percentage of VPAC2+CD90+ cells in lungs of asthmatic mice as compared with the Model group. Four non-consecutive sections from each animal were averaged and compared among experimental groups; n = 3 in each group. Data are represented as mean ± S.E.M. (ΔΔΔp < 0.001, Δp < 0.05 compared with the Control group; ***p < 0.001, **p < 0.01 and *p < 0.05 compared with the Model group; #p < 0.05 compared with the dexamethasone treated group.)

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.